




**ZENITH**  
**EPIGENETICS**



**Developing best and first in class combination therapies for oncology**  
**June 18<sup>th</sup>, 2020**

## Zenith Epigenetics at a Glance

- Zenith Epigenetics is a Canadian private company engaged in developing an advanced oncology drug called ZEN-3694. We are pioneering an “**Epigenetic**” technology that has the ability to make existing oncology drugs work better and longer. We can greatly reduce the cancers’ resistance mechanisms to existing drugs and synergistically benefit in controlling or terminating the cancer.
- Zenith’s unique oncology approach has been advanced to Phase 2b combination therapy trials in the following diseases while demonstrating its positive biological effects on;
  - Metastatic Castrate Resistant Prostate Cancer (mCRPC) – ZEN-3694 in **combination with Pfizer’s Enzalutimide** prostate cancer drug – Phase 2b
  - Triple Negative Breast Cancer (TNBC) in combination **with Pfizer’s PARP inhibitor and in collaboration with Pfizer**. Phase 2 is ongoing
- The following indications are already in planning for development with major pharmaceutical companies with planned launches in 2020 & 2021.
  - ZEN-3694 and a PARP inhibitor for all Breast cancers
  - ZEN-3694 and a PARP inhibitor for Ovarian cancers
  - ZEN-3694 and a PARP inhibitor for Prostate cancer
  - ZEN-3694 in a triple combination with a Merck and a Pfizer drug
  - ZEN-3694 and a checkpoint inhibitor sponsored by a federal group
- Post the first prostate cancer trial which was paid for by Zenith, the balance are being or will be paid for in part or whole by the corresponding partners as ZEN-3694 clearly has the **potential to expand their existing and future revenues**.

Spun out of Resverlogix in June 2013	Private
Estimated Enterprise Value	\$250MM <sup>USD</sup>
Shares Outstanding (Diluted)	~145MM <sup>1</sup>

1. As at April, 2020



## Near Term Activity



A private placement financing effort is ongoing to raise between **\$10MM and \$15MM USD** for the purpose of expediting combination clinical trials for prostate, breast and ovarian cancers. The first \$5MM has already been placed in June 2020. Expected terms for the balance will be similar to the recently announced financing and will apply to accredited investors only.

**Zenith is currently collaborating with Pfizer for development of ZEN-3694** in combination with their PARP cancer technology in a Phase 2 TNBC (Pfizer does not have rights to ZEN-3694). The program should be partnerable with a major pharmaceutical company with some additional data from the ongoing study.





- Our Pfizer collaboration is designed so that they pay 50% of the cost of the TNBC trial.
- Our next partner agreement with any pharmaceutical company is being designed so that the partner will pay 100% of the trial cost for future indications in combination with their PARP or Checkpoint inhibitors.
- The Partner will also need to provide Zenith with a non refundable upfront right of first refusal payment.
- Additionally Zenith will receive milestone payments as each of the three new indications enter final pivotal trials, planned in early 2022 and upon approval.
- A deal is expected to also include substantial royalty payments with an M&A right of first refusal option that can be triggered at any time.



# Breast Cancer - Numerous Patients have shown objective responses, Publications and Presentations Pending

Example 1 - 73 % decrease in target lesion










### Lesion snapshots

	Baseline (10/08/2019)	Follow-up 1 (12/13/2019)
<b>Target lesions</b>		
<b>T01 Lung upper lobe right</b> Lung upper lobe right		
Size	LA: 10.8 mm	LA: 5.0 mm (-53.7% ΔP) Too small
<b>Non-target lesions</b>		
<b>NT01 Lung upper lobe left</b> Lung upper lobe left		
Size	Present	Present


*All progress values are relative to their previous value (ΔP)*

Example 2 - Near complete regression


### Lesion snapshots

	Baseline (09/11/2019)	Follow-up 1 (11/07/2019)	Follow-up 2 (01/06/2020)
<b>Target lesions</b>			
<b>T01 Lymph node supraclavicular right (Level V)</b> Lymph node supraclavicular right (Level V)			
Size	SA: 15.0 mm	Disappeared	Disappeared
<b>T02 Liver Segment VIII</b> Liver Segment VIII			
Size	LA: 29.5 mm	LA: 11.6 mm (-60.7% ΔP)	Too small
<b>T03 Liver Segment III</b> Liver Segment III			
Size	LA: 21.7 mm	LA: 11.7 mm (-46.1% ΔP)	Disappeared

# Prostate Cancer - Durable PSA responses resulting in a cover story publication in “Advanced Therapeutics”



Clinical data and AI platform show that both ZEN-3694 and enzalutamide required for durable PSA response




**FULL PAPER**  
Artificial Intelligence



**Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform**

Allan J. Pantuck,\* Dong-Keun Lee, Theodore Kee, Peter Wang, Sanjay Lakhota, Michael H. Silverman, Colleen Mathis, Alexandra Drakaki, Arie S. Belldegrun, Chih-Ming Ho,\* and Dean Ho\*

**ADVANCED THERAPEUTICS**  
www.advtherap.com



# ZEN-3694 address' drug resistance by re-sensitizing tumors




ZEN3694 has already shown synergistic benefit in numerous combinations of existing drugs.

# Publication Tracking Confirms Huge Growth Area!




## Dramatic growth of publications over the past decade in Epigenetics and BET Inhibition

Publications on Epigenetics



Publications on BET Bromodomain and Zenith & RVX Compounds



Note: Zenith technologies were developed by RVX before being spun out of RVX in 2013

As of May 27<sup>th</sup>, 2020

Source: PubMed Database: Historical Review Q2 2020

# Zenith's Principle Investigators - World Renowned Leaders

## BREAST CANCER

**Memorial Sloan Kettering Cancer Center,** Mark Robson  
**MD Anderson,** Jennifer Litton  
**Jules Bordet, Belgium,** Philippe Aftimos  
**University of Penn,** Payal Shah  
**VHIO, Spain** Mafalda Oliveira  
**START Madrid** – Valentina Boni  
**UZ Leuven** – Kevin Punie  
**Sarah Cannon** – Erika Hamilton

## PROSTATE CANCER

**U of California San Francisco,** Rahul Aggarwal, & Eric Small, MD's  
**Memorial Sloan Kettering Cancer Center,** Wassim Abida, MD, PhD &  
Howard Scher  
**University of Michigan,** Joshi Alumkal, MD







## Key company highlights include;



The development of epigenetic combination cancer therapies that significantly expand the value of existing standard of care therapeutics is the core of our business – we have proven that we can increase pharma’s current revenue streams!

- Differentiated as best in class, **ZEN-3694** can be administered safely in combination with other drugs. Address’ resistance to current Standard of Care therapies.
- **Triple Negative Breast Cancer (TNBC) Pfizer** collaboration extended to Phase 2: This program deals with non germline-BRCA1/2 cancers, representing 70% of the market. We have demonstrated significant clinical activity and plan to publish soon. We are planning to expand to ovarian, HR+ breast and prostate cancers. 
- **Prostate Cancer Program (mCRPC):** Phase 2b, ZEN-3694 + Enzalutamide in androgen receptor inhibition resistant patients. Phase 2 Proof of Concept established, positive feedback from FDA on registration plan. Partnered in China with **NEWSORA – China**.
- **Triple combination study in Androgen Receptor independent CRPC - oncology combination**
- Other PI-initiated studies in solid tumors.



# Company Forward Looking Statement & Contact Info



## Zenith Capital Corp.

### Corporate Update Conference Call & Webcast

June 18, 2020 at 11 am ET

*This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this presentation may include forward looking information relating to relating to a planned private placement by the Company. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our most recent MD&A which are incorporated herein by reference and are available through SEDAR at [www.sedar.com](http://www.sedar.com). The forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and are made as of the date hereof. Zenith disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

**Contact:**

**Investor Relations**

**Email: [info@zenithepigenetics.com](mailto:info@zenithepigenetics.com)**

**Phone: 587-390-7865**

**Website: [www.zenithepigenetics.com](http://www.zenithepigenetics.com)**